Q4 2024 Earnings Call Transcript February 20, 2025 Dynavax Technologies Corporation reports earnings inline with expectations ...

Good day, ladies and gentlemen, and welcome to the Dynavax Technologies fourth quarter and full year 2024 financial results ...

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 25% and 0.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Dynavax Technologies Corp (DVAX) reports record revenue for Heplisav-B, advances in vaccine programs, and strategic financial positioning despite rising R&D costs.

Dynavax Technologies (NASDAQ:DVAX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by William Blair in a note issued to investors on Friday,RTT News reports. William Blair also issued ...

Full Year 2024 Results Key Financial Results Revenue: US$277.2m (up 19% from ...

Dynavax Technologies Corporation ( NASDAQ: DVAX) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - ...

Learn about Deep Track Capital's proxy fight with Dynavax (DVAX) and their push to prioritize Heplisav's growth.

The Emeryville, California-based company said it had net income of 5 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...

Dynavax Technologies (DVAX) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to break-even earnings per share a year ago.

Life sciences investment firm Deep Track Capital is launching a board fight at Dynavax Technologies , pressing for new directors to prioritize the development of the company's hepatitis B vaccine ...